CSL Limited

CHIA:CSL Stock Report

Market Cap: AU$80.6b

CSL Valuation

Is CSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CSL (A$167.77) is trading below our estimate of future cash flow value (A$209.59)

Significantly Below Future Cash Flow Value: CSL is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSL?

Key metric: As CSL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CSL. This is calculated by dividing CSL's market cap by their current revenue.
What is CSL's PS Ratio?
PS Ratio3.7x
SalesUS$15.80b
Market CapUS$57.82b

Price to Sales Ratio vs Peers

How does CSL's PS Ratio compare to its peers?

The above table shows the PS ratio for CSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.4x
TLX Telix Pharmaceuticals
4.3x13.85%AU$5.3b
MSB Mesoblast
33.7x38.05%AU$3.1b
CUV Clinuvel Pharmaceuticals
5.5x7.94%AU$525.5m
ARX Aroa Biosurgery
2.3x12.46%AU$197.2m
CSL CSL
3.7x2.97%AU$80.6b

Price-To-Sales vs Peers: CSL is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (11.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CSL's PS Ratio compare vs other companies in the AU Biotechs Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.16.1x6.6%
CSL CSL
 3.7x2.97%US$57.82b
ARX Aroa Biosurgery
2.3x12.46%US$141.44m
RAD Radiopharm Theranostics
2.7x50.02%US$31.12m
CSL 3.7xIndustry Avg. 16.1xNo. of Companies10PS01632486480+
11 CompaniesEstimated GrowthMarket Cap
Industry Avg.16.1x42.4%
CSL CSL
 3.7x43.62%US$57.82b
No more companies

Price-To-Sales vs Industry: CSL is good value based on its Price-To-Sales Ratio (3.7x) compared to the Australian Biotechs industry average (16.1x).

Price to Sales Ratio vs Fair Ratio

What is CSL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ratio6.1x

Price-To-Sales vs Fair Ratio: CSL is good value based on its Price-To-Sales Ratio (3.7x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CSL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$167.77
AU$162.96
-2.87%
10.78%AU$204.72AU$131.54n/a16
Aug ’27AU$122.51
AU$138.62
+13.15%
19.06%AU$196.99AU$107.51n/a16
Jul ’27AU$118.11
AU$140.25
+18.74%
20.82%AU$201.21AU$105.28n/a16
Jun ’27AU$94.35
AU$140.35
+48.76%
20.47%AU$192.97AU$100.97n/a16
May ’27AU$124.67
AU$196.57
+57.67%
11.76%AU$243.76AU$152.37n/a16
Apr ’27AU$142.22
AU$210.94
+48.32%
13.17%AU$274.58AU$176.04n/a16
Mar ’27AU$146.67
AU$212.64
+44.98%
14.31%AU$270.02AU$175.01n/a15
Feb ’27AU$182.53
AU$227.40
+24.58%
11.73%AU$276.21AU$179.28n/a16
Jan ’27AU$172.97
AU$237.91
+37.55%
12.03%AU$294.71AU$189.00n/a16
Dec ’26AU$182.74
AU$244.34
+33.71%
11.10%AU$296.55AU$196.03n/a16
Nov ’26AU$179.12
AU$244.48
+36.49%
12.32%AU$296.63AU$189.14n/a16
Oct ’26AU$199.04
AU$280.24
+40.80%
8.59%AU$311.60AU$222.27n/a16
Sep ’26AU$210.66
AU$284.80
+35.20%
8.13%AU$312.80AU$225.91n/a17
Aug ’26AU$263.88
AU$315.41
+19.53%
7.07%AU$353.82AU$253.67AU$122.5117
Jul ’26AU$238.65
AU$307.82
+28.98%
6.96%AU$343.88AU$247.88AU$118.1117
Jun ’26AU$247.64
AU$313.70
+26.68%
7.15%AU$353.09AU$244.47AU$94.3517
May ’26AU$252.16
AU$312.43
+23.90%
8.04%AU$355.39AU$246.07AU$124.6717
Apr ’26AU$250.68
AU$319.41
+27.42%
7.44%AU$359.94AU$249.22AU$142.2217
Mar ’26AU$260.33
AU$318.17
+22.22%
7.66%AU$360.07AU$248.53AU$146.6716
Feb ’26AU$281.37
AU$329.71
+17.18%
5.02%AU$353.28AU$286.77AU$182.5316
Jan ’26AU$280.92
AU$340.49
+21.20%
5.95%AU$374.05AU$297.73AU$172.9715
Dec ’25AU$281.22
AU$330.79
+17.63%
6.00%AU$356.98AU$284.14AU$182.7415
Nov ’25AU$282.22
AU$328.58
+16.43%
6.36%AU$355.30AU$278.93AU$179.1215
Oct ’25AU$288.47
AU$313.36
+8.63%
6.43%AU$346.82AU$266.76AU$199.0414
Sep ’25AU$307.16
AU$309.87
+0.88%
9.62%AU$343.65AU$223.28AU$210.6615
Aug ’25AU$311.73
AU$322.16
+3.35%
9.56%AU$367.17AU$232.31AU$263.8815
AU$162.44
Fair Value
3.3% overvalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/22 21:07
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research